Raleigh’s BioDelivery Sciences International (Nasdaq: BDSI) is continuing on its Belbuca run since reacquiring the pain management product from Endo Pharmaceuticals earlier this year.
BDSI announced Friday that Belbuca has received Health Canada approval and that it expects to launch the product in Canada early next year with a commercial partner.
“BDSI has not yet announced a partner for Canada, though we have been in discussions with potential partners. The approval was an important step…
Raleigh’s BioDelivery Sciences International (Nasdaq: BDSI) is continuing on its Belbuca run since reacquiring the pain management product from Endo Pharmaceuticals earlier this year.
BDSI announced Friday that Belbuca has received Health Canada approval and that it expects to launch the product in Canada early next year with a commercial partner.
“BDSI has not yet announced a partner for Canada, though we have been in discussions with potential partners. The approval was an important step…